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Summary 
The Southwest Oncology Group (SWOG) studied the response rate and toxicity of piroxantrone (150 mg/m 2 
q 21 days) in patients with advanced metastatic renal cell carcinoma. Among 32 eligible patients, there were 
no partial nor complete responses. There were two mixed responses. Significant white cell toxicity, anemia, 
nausea, and vomiting were observed. Mild or moderate degrees of fever, malaise, and stomatitis occurred. 
No significant cardiac toxicity was noted. Piroxantrone does not have significant activity as a single agent 
in advanced renal cell carcinoma. 
Introduction 
Piroxantrone is an anthrapyrazole which was syn- 
thesized in an effort to combine the antitumor ef- 
fect of related anthracycline compounds with de- 
creased cardiotoxicity. Synonyms include NSC- 
349174, CI942, DuP 942, oxantrazole, and an- 
thrapyrazole. It appears to cause cell death by DNA 
binding and subsequent strand breaks and inhibi- 
tion of DNA, RNA, and protein synthesis [1,2]. 
Piroxantrone has demonstrated antineoplastic ac- 
tivity in several animal tumor systems, including: 
B16 melanoma; M5076 and Ridgeway sarcoma; 
L1210 and P388 leukemias; MX-1 and 16C mam- 
mary carcinoma. Some of these tumor models were 
resistant to doxorubicin and mitoxantrone [3,4]. 
Two separate phase I clinical trials have been 
published, both using a single-dose one hour infu- 
sion every 21 days [5,6]. Predictable, manageable 
toxicities were noted at dose levels around 150 
mg/m 2. The most important of these was my- 
elosuppression. No significant cardiac toxicity was 
seen. The Southwest Oncology Group (SWOG) 
studied piroxantrone in several different diseases; 
this report details the phase II results seen in pa- 
tients with renal cancer. Study objectives were 
twofold: first, to assess the response rates and se- 
cond, to assess the toxicities of piroxantrone ad- 
ministered every 21 days. 
Materials and methods 
Eligibility included a histologic confirmation of 
renal cell carcinoma, no prior chemotherapy, bi- 
dimensially measurable disease outside of previous 
radiation therapy ports, life expectancy of at least 
six weeks, performance status of  2 or better 
(SWOG criteria), and absence of a recent my- 
ocardial infarction (within six months) or history of 
congestive heart failure or significant cardiac dys- 
rhythmia. Patients were to have recovered from 
prior surgery and radiation. Prior radiation must 
have included less than 25% of the bone marrow. 
Concomitant radiation was not allowed. While the 
patient may have received prior hormonal therapy 
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or cimetidine or coumarin, these could not be 
delivered concomitantly with the piroxantrone. 
Laboratory criteria for eligibility included a white 
blood cell count greater than or equal to 4,000/~1, 
platelet count greater than or equal to 100,000//~1, 
and serum bilirubin, SGOT (AST), and creatinine 
within institutional upper limits of normal. A 
radionuclide ventriculogram (gated-pool image; 
MUGA scan) prior to entry must have documented 
a left ventricular ejection fraction of at least 45%. 
All patients were provided information regarding 
the investigational nature of  the study and were re- 
quired to sign a written document of  informed 
consent in keeping with institutional and FDA 
guidelines. 
Patients received an initial dose of  piroxantrone 
at 150 mg/m 2 in 5% dextrose, at a concentration 
of 1 mg/ml,  infused over one hour and repeated ev- 
ery 21 days. Subsequent doses were administered at 
21 day intervals and increased by 20% if the nadir 
granulocyte count was greater than 1,500/tA and 
platelet nadir exceeded 100,000/IA. For nadir 
granulocyte counts between 500-1500 or platelet 
counts between 50,000-100,000/~1, the dose re- 
mained the same. For nadir granulocyte counts less 
than 500/#1 or platelet counts less than 50,000//A, 
the subsequent dose of piroxantrone was decreased 
by 20%. Two downward and two upward dose ad- 
justments were allowed. 
Study patients underwent history and physical 
examination every three weeks, and serum chemis- 
tries were evaluated at the same interval. Blood 
counts were obtained weekly. Radionuclide ven- 
triculograms were repeated after the fourth course 
of piroxantrone, and prior to every third course 
thereafter. Patients were removed from the study if 
their cardiac ejection fraction dropped by more 
than 10% from baseline. Tumor measurements 
were made every 42 days. Response criteria were 
standard for a phase II trial: complete remission 
(CR), which required disappearance of all clinically 
detectable disease for at least three weeks; partial 
remission (PR) which required a 50% shrinkage in 
the sum of  the products of the perpendicular di- 
ameters of  measured lesions for a minimum of  
three weeks, with no simultaneous increase in the 
size of any lesion or the appearance of any new le- 
sions; progression, which required at least a 50% 
increase in the sum of products of measurable le- 
sions, or appearance of a new lesion. Patients with 
progressive disease or unacceptable toxicity were 
taken off  study. 
Results 
Piroxantrone was given to 34 patients. Two of these 
patients were ineligible due to inadequate baseline 
assessments. Of  the remaining 32, one refused 
treatment after the first cycle, and two had inade- 
quate follow-up. In reckoning response, these three 
patients were assumed to be non-responders. There 
were 28 males and 6 females. The median age was 
60, with a range of 36 to 79. Four patients had 
received a biological response modifier, 2 had 
received hormonal  treatment, and one had received 
both of  these. One half of  the patients (17) had a 
prior nephrectomy. Except for 10 patients all of  
those entered on the trial received two or more cy- 
cles of chemotherapy. Of  these 10 patients, one re- 
fused further treatment due to toxicity. The others 
were taken off  due to disease progression. No com- 
plete nor partial responses were seen. There were 2 
mixed responses, in which marked shrinkage in 
lung lesions was noted at the same time that disease 
progressed elsewhere - in the central nervous sys- 
tem in one case, and in the kidney in the other case. 
One patient remains on the drug with stable disease, 
having received 14 cycles of  chemotherapy for a cu- 
mulative dose of  1,933 mg/m 2. The stability of her 
disease could simply reflect the natural history of 
her particular disease; she had a hilar and a medi- 
astinal mass which had progressed only minimally, 
without treatment, in the 6 months prior to going 
on study. 
A median of 2.9 courses (range 1 - 14) of  piroxan- 
trone was given to the 32 eligible patients. The cu- 
mulative amount  of piroxantrone administered per 
patient ranged from 150 mg/m 2 to 1,933 mg/m 2 
with a median of  428 mg/m 2. There were 13 dose 
escalations and 6 dose reductions given per pro- 
tocol criteria. 
Toxicity is summarized in Table 1. Toxicity grad- 
ing is by standard SWOG criteria. The major side 
Table 1. Toxicities 
Toxicities Grade 
(0) (1) (2) (3) (4) 
None Mild Mod Severe LT* 
Granulocytopenia 23 1 3 3 4 
Leukopenia 18 3 13 0 0 
Anemia 19 4 6 4 1 
Nausea 17 11 4 2 0 
Vomiting 24 7 2 1 0 
Alopecia 27 5 2 0 0 
Fever without infection 28 2 4 0 0 
Stomatitis 30 3 1 0 0 
Hypercalcemia 33 0 1 0 0 
Dysrhythmia 33 1 0 0 0 
* LT = life-threatening 
effect in this population, involving 65% of pa- 
tients, was hematologic. Four patients experienced 
Grade 4 granulocytopenia. One of these patients in- 
advertently and inappropriately received an escalat- 
ed dose with his second course of treatment. One 
patient experienced Grade 4 anemia. Severe (Grade 
3) anemia was noted in 4 patients, severe nausea in 
2 patients, and severe vomiting in 1 patient. One 
patient experienced palpitations with an irregular 
pulse before and three weeks after his fourth, and 
final, course of piroxantrone. This occurred at the 
same time that his hemoglobin had dropped to be- 
low 9.0. Other than this, no instances of acute nor 
chronic cardiac toxicity were noted. Alopecia was 
minimal. Other toxicities are noted. 
One patient experienced extravasation of pirox- 
antrone into the dorsum of her hand. She was 
hospitalized and observed overnight. The dorsum 
of her hand became swollen, tender, and dusky for 
approximately 48 hours, then normalized. There 
were no long-term sequelae. 
The overall median survival was 5.4 months, 
with a median follow-up for censored cases of 4.3 
months (range 1.3-8.9 months). 
Discussion 
Patients with advanced renal cell carcinoma remain 
relatively resistant to any form of systemic chemo- 
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therapy. This dose schedule of piroxantrone was 
reasonably well tolerated, although there was some 
significant white cell depression. While there is evi- 
dence that extravasated piroxantrone could have 
toxicity similar to doxorubicin, with potential for 
tissue necrosis, this did not occur with the patient 
who extravasated [7]. The finding that there were 
no responders among 32 eligible patients strongly 
suggests that piroxantrone in this dose schedule has 
no role in the treatment of patients with advanced 
renal cell carcinoma. 
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